Use of Letermovir for Salvage Therapy for Resistant Cytomegalovirus in a Pediatric Hematopoietic Stem Cell Transplant Recipient.
Publication
, Journal Article
Kilgore, JT; Becken, B; Varga, MG; Parikh, S; Prasad, V; Lugo, D; Chang, Y-C
Published in: J Pediatric Infect Dis Soc
September 17, 2020
We present here the first published use of letermovir for the treatment of resistant cytomegalovirus (CMV) in a pediatric patient. A 14-year-old girl underwent a double unrelated umbilical cord blood transplantation to treat her sickle cell disease (hemoglobin SS) and developed ganciclovir-resistant CMV DNAemia with end-organ involvement that was treated successfully with a combination of foscarnet and letermovir. After she was transitioned to letermovir monotherapy for secondary prophylaxis, she developed recurrent DNAemia with laboratory-confirmed ganciclovir, foscarnet, and letermovir resistance.
Duke Scholars
Published In
J Pediatric Infect Dis Soc
DOI
EISSN
2048-7207
Publication Date
September 17, 2020
Volume
9
Issue
4
Start / End Page
486 / 489
Location
England
Related Subject Headings
- Salvage Therapy
- Quinazolines
- Immunocompromised Host
- Humans
- Hematopoietic Stem Cell Transplantation
- Female
- Drug Resistance, Viral
- Cytomegalovirus Infections
- Antiviral Agents
- Adolescent
Citation
APA
Chicago
ICMJE
MLA
NLM
Kilgore, J. T., Becken, B., Varga, M. G., Parikh, S., Prasad, V., Lugo, D., & Chang, Y.-C. (2020). Use of Letermovir for Salvage Therapy for Resistant Cytomegalovirus in a Pediatric Hematopoietic Stem Cell Transplant Recipient. J Pediatric Infect Dis Soc, 9(4), 486–489. https://doi.org/10.1093/jpids/piz050
Kilgore, Jacob T., Bradford Becken, Matthew G. Varga, Suhag Parikh, Vinod Prasad, Debra Lugo, and Yeh-Chung Chang. “Use of Letermovir for Salvage Therapy for Resistant Cytomegalovirus in a Pediatric Hematopoietic Stem Cell Transplant Recipient.” J Pediatric Infect Dis Soc 9, no. 4 (September 17, 2020): 486–89. https://doi.org/10.1093/jpids/piz050.
Kilgore JT, Becken B, Varga MG, Parikh S, Prasad V, Lugo D, et al. Use of Letermovir for Salvage Therapy for Resistant Cytomegalovirus in a Pediatric Hematopoietic Stem Cell Transplant Recipient. J Pediatric Infect Dis Soc. 2020 Sep 17;9(4):486–9.
Kilgore, Jacob T., et al. “Use of Letermovir for Salvage Therapy for Resistant Cytomegalovirus in a Pediatric Hematopoietic Stem Cell Transplant Recipient.” J Pediatric Infect Dis Soc, vol. 9, no. 4, Sept. 2020, pp. 486–89. Pubmed, doi:10.1093/jpids/piz050.
Kilgore JT, Becken B, Varga MG, Parikh S, Prasad V, Lugo D, Chang Y-C. Use of Letermovir for Salvage Therapy for Resistant Cytomegalovirus in a Pediatric Hematopoietic Stem Cell Transplant Recipient. J Pediatric Infect Dis Soc. 2020 Sep 17;9(4):486–489.
Published In
J Pediatric Infect Dis Soc
DOI
EISSN
2048-7207
Publication Date
September 17, 2020
Volume
9
Issue
4
Start / End Page
486 / 489
Location
England
Related Subject Headings
- Salvage Therapy
- Quinazolines
- Immunocompromised Host
- Humans
- Hematopoietic Stem Cell Transplantation
- Female
- Drug Resistance, Viral
- Cytomegalovirus Infections
- Antiviral Agents
- Adolescent